In the News
Marketing applications for biopharmaceuticals: Considerations for different jurisdictions – Part 2
In this two-part series, John Watkins and Clare Ryder highlight the similarities and differences in global submission requirements.
2017 year in preview: Trends revisited
Jai Balkissoon, M.D., and Elizabeth Madichie offer their thoughts one year later on the Cancer Moonshot and combination therapies, two of the key trends PharmaVOICE identified for 2017.
Trending 2018: What does the future hold?
Susan Atkinson comments on risk-based monitoring in this feature in which industry experts identify the trends they think will impact life sciences in the coming year.
Bending the Cost and Time Curve of Drug Development through the Use of Biomarkers
In this article written by Katie Matys and Janine McKnight, the authors discuss how the right biomarker can make all the difference in a drug-development program.
Marketing applications for biopharmaceuticals: Considerations for different jurisdictions – Part 1
In this two-part series, John Watkins and Clare Ryder highlight the similarities and differences in global submission requirements.
Why You Should Care About Real-World Evidence (A Lot)
Radek Wasiak of Evidera comments on real-world evidence in part one of this three-part series.
Functional Service Partnerships: A Case Study for CRO Resource Management
In this article written by Denise Moody, Tim King and Ranjit Bains, the authors review an FSP in which PPD reduced a client’s annual operational spend by assuming responsibility for clinical monitoring and site support.
Real-World Evidence & The 21st Century Cures Act — What You Need To Know
Radek Wasiak of Evidera comments on real-world evidence in part two of this three-part series.
How Interested Is The FDA In Real-World Evidence?
Radek Wasiak of Evidera comments on real-world evidence in part three of this three-part series.